Technical Analysis for TGTX - TG Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
13.7 | -2.35% | -0.33 |
TGTX closed down 2.35 percent on Friday, January 17, 2020, on 1.34 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Very Strong | Up | Up | Up |
| Historical TGTX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week High | Strength | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Slingshot Bullish | Bullish Swing Setup | -2.35% | |
| New 52 Week High | Strength | -2.35% | |
| Upper Bollinger Band Walk | Strength | -2.35% | |
| Outside Day | Range Expansion | -2.35% | |
| Wide Bands | Range Expansion | -2.35% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/13/2019
- Sector: Healthcare
- Industry: Biotechnology
TG Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The company is developing two advanced therapies targeting hematological malignancies. The TGTX-1101 (ublituximab) is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes, which is in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. The TGR-1202 is an orally available PI3K delta inhibitor believed to be important in the proliferation and survival of B-lymphocytes. TG Therapeutics, Inc. is headquartered in New York, New York.
Biopharmaceutical Cancer Treatment Of Cancer Monoclonal Antibodies Lymphoma Antibody Drug Conjugates Hematological Malignancies Camidanlumab Tesirine Cd20
Biopharmaceutical Cancer Treatment Of Cancer Monoclonal Antibodies Lymphoma Antibody Drug Conjugates Hematological Malignancies Camidanlumab Tesirine Cd20
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 14.89 |
| 52 Week Low | 3.87 |
| Average Volume | 2,225,286 |
| 200-Day Moving Average | 7.68 |
| 50-Day Moving Average | 9.73 |
| 20-Day Moving Average | 11.88 |
| 10-Day Moving Average | 12.97 |
| Average True Range | 0.80 |
| ADX | 52.14 |
| +DI | 37.15 |
| -DI | 6.62 |
| Chandelier Exit (Long, 3 ATRs ) | 12.48 |
| Chandelier Exit (Short, 3 ATRs ) | 12.06 |
| Upper Bollinger Band | 14.53 |
| Lower Bollinger Band | 9.22 |
| Percent B (%b) | 0.84 |
| BandWidth | 44.72 |
| MACD Line | 1.24 |
| MACD Signal Line | 1.10 |
| MACD Histogram | 0.1449 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 15.62 | ||||
| Resistance 3 (R3) | 15.80 | 15.35 | 15.30 | ||
| Resistance 2 (R2) | 15.35 | 14.86 | 15.26 | 15.19 | |
| Resistance 1 (R1) | 14.52 | 14.56 | 14.30 | 14.34 | 15.09 |
| Pivot Point | 14.07 | 14.07 | 13.95 | 13.98 | 14.07 |
| Support 1 (S1) | 13.24 | 13.58 | 13.02 | 13.06 | 12.31 |
| Support 2 (S2) | 12.79 | 13.28 | 12.70 | 12.21 | |
| Support 3 (S3) | 11.96 | 12.79 | 12.10 | ||
| Support 4 (S4) | 11.78 |
